Royalty Report: Drugs, ribonucleic acid, Diagnostic – Collection: 237275

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 16

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 16

Primary Industries

  • Drugs
  • ribonucleic acid
  • Diagnostic
  • Drug Discovery
  • Genome
  • Software
  • Medical Info
  • Cancer
  • Medical
  • Test/Monitoring
  • Content
  • Surgical
  • Respiratory
  • DNA
  • Device
  • Assay
  • Therapeutic
  • Proteins
  • Arthritis

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 237275

License Grant
Licensee obtained a non-exclusive license to practice certain patent and other rights of Licensor.  This amendment add definition and changes language, as well as updating the royalty information.
License Property
The replaced Gene definition shall refer to a nucleic acid sequence representing or encoding a distinct messenger RNA or protein as well as polymorphic variants of such sequence, provided that such polymorphic variants must have at least ninety-nine and nine tenths percent (99.9%) homology with the underlying gene.
Field of Use
Licensed Genetic Analysis Field shall mean the measurement of the presence, absence or level of an expressed Gene in cells for use in pharmaceutical and diagnostic research provided that any one Nucleic Acid Array shall be capable of measuring up to but not exceeding 7,000 Unique Elements using up to but not exceeding 14,000 Spots.

IPSCIO Record ID: 294285

License Grant
For the Exclusive Licenses, Licensor grants an exclusive license including the right to sublicense, under the Licensor Patent Rights and Licensor Technology to develop, make, have made, use, sell, offer for sale and import Biomolecules and Licensed Products in the Territory.

For the Non-Exclusive Research Licenses, Licensor grants a non-exclusive, irrevocable, perpetual license in the Territory, to use solely for research done by Licensee or its Affiliates or by Third Party contractors for Licensee or its Affiliates the Licensor Technology, excluding any Licensor Technology that is now or hereafter during the Term covered by claims in issued patents or published patent applications disclosed to Licensee during the Term.

License Property
Licensor owns or controls certain patents, patent applications, technology,know-how and scientific and technical information relating to Biomolecules and Licensed Products.

Applicable Biomolecule means a Biomolecule as to which Licensor at any time during the Term commenced IND-enabling toxicity studies or clinical trials.

Product means any product, including any pharmaceutical product or diagnostic product, which contains any Biomolecule, either alone or in combination with any other active pharmaceutical ingredient, in all formulations and strengths for all uses.

Combination Product means any pharmaceutical product containing a Biomolecule and one or more other active phannaceutical ingredients.

Field of Use
License relates to Licensor’s human gene RTP-801 and to molecules that modify its expression or function under a new agreement between the two companies. RTP-801 is involved in the development of pathologic blood vessels that accelerate the progression of age-related macular degeneration (AMD).   Based on preclinical models, it is believed that AMD can be treated by blocking the expression of the RTP-801 gene through RNA interference or RNAi.

Licensee has extensive experience and expertise in the development and commercialization of pharmaceutical products.  Licensor is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi interference or RNAi-based therapeutics.

IPSCIO Record ID: 299232

License Grant
Licensor grants a nontransferable, nonexclusive, worldwide license under Licensors Patent Rights and Technical Information to make, but not have made, use for internal array development programs and pharmaceutical or diagnostic research, such use rights not including the right to license or distribute expression databases, or perform therapeutic or pharmaceutical development on a service or similar basis, import, lease, distribute, offer for sale, and sell, in the case of products other than software;  Genetic Analysis Technology Consortium or GATC Compliant Nucleic Acid Arrays, and.  GATC Compliant Systems for use with and only for use with GATC Compliant Nucleic Acid Arrays licensed hereunder, all to the extent that such Nucleic Acid Arrays or Systems are covered by Licensor Patent Rights and/or Licensors Technical Information.

Licensor grants to Licensee a nontransferable, nonexclusive, worldwide, royalty-free license under Licensor -Patent Rights to make (but _not have made); ·and· use Array Makers for internal array.
development and manufacturing development programs.

License Property
Licensor has Technical Information which includes a software suite for data extraction and image processing.

The Licensed software packages are GeneChip® System Software and GeneChip Expression Analysis Software.

System shall mean one or more readers, hybridization devices, computer work stations, and/or single copies of software associated therewith specifically configured for use with Nucleic Acid Arrays and to be used for extraction and processing of data from such Nucleic Acid Arrays, and not including, for example, Array Makers.

Array Maker shall mean a device designed to fabricate Nucleic Acid Arrays by Mechanical Fabrication Methods and specifically configured to fabricate only Nucleic Acid Arrays only by Mechanical Fabrication Methods.

Gene shall refer to a nucleic acid sequence encoding a distinct messenger RNA and protein as well as polymorphic variants of such sequence.

Field of Use
The field of use is software useful in connection with Nucleic Acid Arrays, and to be used for extraction and processing of data from such Nucleic Acid Arrays.

IPSCIO Record ID: 289169

License Grant
Licensor grants to the Swiss Licensee a worldwide, semi-exclusive license, without the right to sublicense, under the Licensor Licensed Patents to research, develop, make, have made, import, use, offer for sale and sell Licensor Licensed Products for use in the Field.

For Licensor Transplantation Field License, Licensor grants a worldwide, non-exclusive license, without the right to sublicense, under Licensor Licensed Patents to research, develop, make, have made, import, use, offer for sale and sell Licensor Licensed Products for use in the Transplantation Field.

For Licensor Future HGV Sequence Patent Rights, Licensor grants to a non-exclusive option to obtain one or more non-exclusive, worldwide licenses, or sublicenses, as the case may be, with a right to sublicense to Licensee Affiliates only, under the Licensor Future HGV Sequence Patent Rights, to make, have made, use, import, offer for sale and sell Licensor Licensed products.

License Property
Licensed Patents means the Licensor Licensed Patents and the Licensee Optioned Patents.

Products  means reagents, compositions or kits suitable for use in the Field or the Transplantation Field.

The patents include NANBV Diagnostics and Vaccines;  Heteroduplex Tracking Assay for Gene Typing; and, Polynucleotide Probes Useful for Screening for HCV.

Both Parties currently own or control certain patent rights relating to the hepatitis C virus (HCV).

Field of Use
The Licensees purpose is for use in assays for the detection of nucleic acid sequences for use in in vitro diagnostics, excluding use in Blood Screening, but without limiting the effect of the Blood Screening Agreement.

Field means the commercial use of human in vitro diagnostic products that detect nucleic acid sequences of HCV. Expressly excluded from the Field are products in Blood Screening; products specifically labeled or promoted for use in the Transplantation Field.

Transplantation Field means the commercial use of products that detect nucleic acid sequences for the screening of any biological materials intended for transfusion or transplantation, in each case from any donor, including autologous donors, other than the transfusion or transplantation of blood or its derivatives, components or replacements.

IPSCIO Record ID: 344567

License Grant
Licensor grants
For the Development License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Profit-Share Territory, and an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Royalty Territory.

For the Commercialization License, an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology to Commercialize Licensed Products in the Field in the Territory.

For the Manufacturing License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Manufacture or have Manufactured Licensed Products for Development and Commercialization in the Field for the Territory.

License Property
Patents includes, among other
RNAI Modulation of RSV and Therapeutic Uses Thereof,
Inhaled Treatment for RSV,
Methods and Compositions for Prevention or Treatment of RSV Infection,
Model for RSV Infection,
Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences,
Use of Double Stranded RNA For Identifying Nucleic Acid Sequences That Modulate the Function of a Cell, and, Influenza siRNA Molecules, Expression Constructs. Compositions. and Methods of Use.

Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

ALN-RSV01 is a synthetic double-stranded RNA (dsRNA) oligonucleotide formed by the hybridization of two partially complementary single-strand RN As in which the 3 ends of each strand are capped with two thymidine units (dT).

ALN-RSVO1 drug product is formulated as a sterile phosphate-buffered solution for dilution with normal saline prior to administration.

Licensed Products means any RNAi Product directed to RSV.

RSV means all strains of the respiratory syncytial virus.

RSVOl Product means any product containing Licensors proprietary composition known as ALN-RSVO1.

RSV02 Product means any product containing Licensors proprietary composition designated by the JSC as ALN-RSV02.

Field of Use
ALN-RSV01 is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients, as well as several other potent and specific second-generation RNAi-based RSV inhibitors in pre-clinical studies.

Directly Competitive Product means any therapeutic or prophylactic product that specifically targets RSV. For avoidance of doubt, Directly Competitive Product as to a Party shall not include a product with broad antiviral activity that may also target RSV as long as any Development of such product as a treatment or
prophylaxis of RSV in humans has been limited to discovery, research and preclinical Development work up to, but not including, IND-enabling studies.

Licensee will develop and commercialize such therapeutic RNA interference products for the treatment of respiratory infections in humans caused by RSV, throughout the world, excluding Japan and certain other countries in Asia.

IPSCIO Record ID: 279354

License Grant
Licensor grants to Irish Licensee an exclusive license under the Licensor Patents to make (subject to Licensor’s manufacturing rights set forth below), use, sell, and offer for sale in any country of the world Licensed Products in the Field. Neither Licensee nor Licensor will have the right to develop or commercialize Licensed Products outside the Field without prior written consent of the other Party.

Licensor grants to Licensee (a) an exclusive license to use in any country of the world any method or composition claimed by the Licensor Patents, and (b) a non-exclusive license to use in any country of the world any Licensor Know-How, to research in the Field Lead Compounds, Development Compounds, Backup Compounds, and Licensed Products.

License Property
Licensed Product means a Development Compound for which the Parties obtain the approval from any Regulatory Authority to sell for use by the general public in the Field.

Licensor Patents means a) the patents and applications listed; b) any application that claims priority to the foregoing patents and applications; and c) any patent that issues from any of the applications described in clauses a) and b) above.
US Patent #6,506,559 – Genetic inhibition by double-stranded RNA
US Patent #6,117,657 – Non-nucleotide containing enzymatic nucleic aci
US Patent #6,586,238 – Enzymatic nucleic acids containing 5-and or 3-cap structures

Lead Compound is a Lead selected by JSC for evaluation in the Field.

Development Compound means a Pre-Development Compound that the JSC has designated for clinical development.

Compound means a composition comprising one or more siNAs as active ingredients, known as of the Effective Date or discovered pursuant to this Agreement subsequent to that date, against the Licensee Named Targets in the Field.

Backup Compound means a Lead Compound that the JSC has selected as a backup candidate for clinical development.

JSC means the Joint Steering Committee.

Field of Use
Field means conditions and diseases affecting the eve and treatments for such conditions and diseases. Such conditions and diseases include, for example, diabetic retinopathy and ocular adenoviral infection, but this does not mean that the Field encompasses the treatment outside the eye of diabetes or adenoviral infection, respectively.

Licensee is to develop Sirna-027, a RNAi-based therapeutic currently in Phase 1 for age-related macular degeneration (AMD), and to discover and develop other RNAi-based therapeutics against select gene targets in ophthalmic diseases.

IPSCIO Record ID: 289173

License Grant
Party A, a Canadian University, hereby assigns to Licensee all of Party A’s right, title and interest in and to U.S. Patent Application No. 11/807,872, with no additional payment due to Party B and will record such assignment with the U.S. Patent and Trademark Office.

The Parties shall direct their respective counsel to execute Stipulations of Dismissal with Prejudice dismissing all claims and counterclaims that were or could have been asserted in the Massachusetts State Court Action, U.S. Infringement Action, Canadian Infringement Action, and B.C. Action, and in the case of the Interference Proceeding, a Request for Adverse Judgment providing that Licensee concedes priority to Party A with respect to all claims that correspond to Counts 1-5, i.e., claims 34, 36, 38, and 40-43 of Party A U.S. Application 11/807,872; claims 1-6, 8, 10, 12-18, 21-22, and 32-33 of Licensee U.S. Patent 7,718,629; and claims 32-38 of Licensee U.S. Application 13/165,568, and requesting that an adverse judgment be entered against Licensee as to these claims and priority be awarded to Party A for U.S. Application 11/807,872.

License Property
U.S. Patent 7,718,629 – Compositions and methods for inhibiting expression of Eg5 gene
Patent certains to intellectual property (IP) elements related to lipid nanoparticle (LNP) technology for RNAi therapeutics.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development.

Field of Use
By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon.

IPSCIO Record ID: 299237

License Grant
Licensor hereby grants to Licensee
— a non-exclusive license under the Patent Rights, to make, have made, use, and/or sell Licensed Products for human and non-human applications;
— the right under the Patent Rights to grant to an Affiliate a sublicense; and,
— the right under the Patent Rights to grant to Product Development Partner(s) a single sublicense for each specific application of Licensed Product.
License Property
The patent properties cover the T7 technology, such as, Cloning and Expression of the Gene for Bacteriophage TI RNA Polymerase.

The Designated Product shall mean a protein or other product produced through use of the T7 technology.

SGN-10 is a single-chain immunotoxin that binds to cancer cells and kills them by delivering a protein toxin inside the cell. SGN-10 is composed of the receptor binding portion of the BR96 monoclonal antibody and a truncated portion of a protein toxin called  Pseudomonas    exotoxin A. SGN-10 is currently in two phase I clinical trials.

The term 'Patent Rights' shall mean
    1.  United States Patent No. 4,952,496 entitled 'Cloning and Expression of the Gene for Bacteriophage T7 RNA Polymerase', and any reissue thereof;

    2.  U.S. Patent No. 5,693,489 entitled 'Cloning and Expression of the Gene for Bacteriophage T7 RNA Polymerase', and any reissue thereof;

Field of Use
The field of use is to produce anti-cancer products.

IPSCIO Record ID: 144892

License Grant
Licensor grants a non-exclusive, non-transferable license under Patent Rights to practice Licensed Methods in the Field within Licensors laboratories and to make, have made, use, and export Licensed Products solely for use byLicensee, in the practice of Licensed Methods in the Field. License grant shall not include the right to sell Licensed Product and/or Licensed Method to third parties.
License Property
Licensor owns certain patents covering compositions and processes for detecting ribosomal nucleic acid subsequences belonging to groups of non-viral organisms.

The patents refer to Methods for Detection. Identification and Quantification of NonViral Organisms.

Field of Use
The Field shall mean the performance of human, clinical diagnostic Assays and Assay Series using one or more nucleic acid probes, including peptide nucleic acid probes and probes with modified sugar or phosphate groups, which are designed to detect whether or not bacteria are present in a sample by hybridizing to one or more pan-bacterial regions of ribosomal nucleic acid, whether ribosomal RNA or ribosomal DNA, in order to determine the presence or amount of bacteria which may be present in a human sample. 'Field' shall not include Assays and Assay Series only to detect, quantitate or identify any group of organisms less than or different than that encompassing all bacteria.

IPSCIO Record ID: 203261

License Grant
Licensor grants an exclusive, sublicenseable, non-transferable license, under the Product IP, to research, develop, use, make, have made, market, offer to sell, sell, have sold, distribute, import, export and otherwise commercialize Atonal Vectors, Gene Fragments and/or Products in the Field in the Territory;

a non-exclusive, sublicensable, non-transferable license, under the Product IP to use, make, have made, import and export the Adenovectors solely for research purposes in the Field in the Territory and exercising the license grants set forth;

a non-exclusive, sublicenseable, non-transferable license, under the Production IP, to research, develop, use, make, have made, market, offer to sell, sell, have sold, distribute, import, export and otherwise commercialize Atonal Vectors, Gene Fragments and/or Products in the Field in the Territory; and

– a non-exclusive, sublicensable, non-transferable license, under the Production IP, to use, make, have made, import and export the Adenovectors solely for research purposes in the Field in the Territory and exercising the license grants set forth.

License Property
Licensor has developed Adenovectors, Atonal Vectors and Gene Fragments and possesses certain intellectual property relating thereto.

Intellectual property related to the Licensor's atonal gene program and atonal adenovectors, as well as the Licensor's hearing loss and balance disorders program and its adenovector platform.

Field of Use
The collaboration is for all fields of use.

IPSCIO Record ID: 263967

License Grant
This license agreement is Included with an asset purchase agreement between this Licensee/Seller and a Third Party Buyer.

University hereby grants to Licensee a right and license to make, have made, use, lease, offer to sell, sell, otherwise commercially dispose of, export and import Licensed Products,  to practice Licensed Processes, in each case directly or by sublicense and only for commercial purposes, including providing services to third parties and for Licensees research and/or development in the Field of Use within the Territory during the Term.  

For the Option,  University hereby grants Licensee an option to acquire a non-exclusive, worldwide, royalty-bearing license within the Field of Use under the Optioned Patent Rights to make, have made. use, sell and offer for sale products, processes and services within the Field of Use.

License Property
The intellectual property relates to Sequencing of Biopolymers by Mass Spectrometry.

The Products associated with the Claimed Technologies are specifically SpectroCHlPs; QGE Software;  and,  QGE assays sold through Assays by Licensee. The Products may be amended from time to time.

Field of Use
The field of use is all uses.

IPSCIO Record ID: 237243

License Grant
Licensor grants to the United Kingdom Licensee a non-exclusive license, without the right to sublicense, in the territory in the field of use and under the Patent Rights to research, develop, make, have made, use, sell, have sold, offer for sale, have offered for sale, import, and export Licensed Products, and research, develop, use, and practice Licensed Processes only for the purposes of manufacturing or having manufactured the Licensed Products.

Licensor grants a non-exclusive license, without the right to sublicense, in the Territory to conduct preclinical research and/or pre-Phase II clinical trials ( or the equivalent of pre-Phase II clinical trials in the U.S. or other countries) involving the use of Licensed Products in indications outside of the Field of Use.

License Property
The Licensed Product means the first three (3) short consensus repeat protein domains of human complement receptor type 1 (CRI), derivatized to include a myristoyl peptide, having Licensees designation -070 or any successor product of such -070 which is an optimization or derivative of -070, the development, manufacture, use, sale, offer for sale, importation or distribution.
Field of Use
The field of use means the treatment of rheumatoid arthritis.

IPSCIO Record ID: 344587

License Grant
Licensor grants to the Canadian Licensee an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology and under the Licensor Core Technology Patents, in each case solely to develop, make, have made, use, sell, offer for sale, have sold and import Products.
License Property
Licensor is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to identify and commercialize novel drugs.

Antisense Compound means an oligomeric compound or analog, mimic or mimetic thereof having a sequence that is partially or wholly complementary to the sequence of a messenger RNA (pre-mRNA or mRNA), viral RNA, or noncoding RNA that directly modulates RNA expression.

Product means a pharmaceutical preparation comprising any single TS ASO or Tandem selected by Licensee. After the Project Plan has been completed, the Parties will append to this Agreement the specific sequence and chemistry of each TS ASO which constitutes the active pharmaceutical ingredient in each Product.

TS ASO means a single-stranded oligonucleotide or an analog thereof that hybridizes to TS mRNA using Watson-Crick base pairing and inhibits production of TS via an RNase-H mechanism.

1. U.S. Patent No. 6,001,1653
2. PCT Publication No. WO 93/13121
3. U.S. Patent. 5,914,396
4. U.S. Patent 61451,991
5. U.S. Patent No. 6,166,197
6. U.S. Patent No. 51919,619
7. U.S. Patent No. 5,962,425
8. U.S. Patent No. 6,143,881
9. U.S. Patent No. 5,969,116
10. U.S. Patent No. 6,346,614
11. U.S. Patent No. 6,399,754
12. U.S. Patent No. 6,326,199

Field of Use
The field of use is the identification of a lead TS ASO targeted to inhibit Thymidylate Synthase.

The drug is an antisense inhibitor of thymidylate synthase (TS), a well-known drug target that protects cancer cells from the effects of several chemotherapy treatments. In preclinical studies, antisense inhibition of TS suppressed human tumor cell growth and overcame tumor cell resistance to marketed TS-targeted drugs.

TS is an important target in a wide variety of cancers including, colorectal, breast, stomach, esophageal, head and neck cancers, and mesothelioma; it is of increasing importance in non-small cell lung cancer. In addition to interfering with the effectiveness of chemotherapy, the TS gene may also participate in causing cancer. TS is a target for several chemotherapy agents, including 5-fluorouracil (5-FU), pemetrexed (Alimta®), and raltitrexed (Tomudex®).

IPSCIO Record ID: 299242

License Grant
English Licensor hereby grants to Licensee and Licensee accepts, a non-exclusive, royalty-bearing, worldwide sub-license under the Licensor Patent Rights to manufacture, have manufactured and use Nucleic Acid Arrays for internal purposes only, to create and contribute to the creation of Licensee Ratio-based Databases, and to Supply and offer for Supply Royalty-Bearing Services, in each case in all fields other than the Excluded Fields.
License Property
Nucleic Acid Array means an array of nucleic acids attached to a solid support.

Licensee Ratio-Based Database means a Database containing relative levels of expressed genes within or between cells wherein such Database may be built from data where measurements from one RNA sample are compared with those from another RNA sample; provided, however, a Licensee Ratio-based Database shall in no event include an Incyte Expression Database.

Resolver Software means Licensees software package with features.

Instrument means readers, fluids stations, hybridization devices, sample logging, handling and processing systems, detection and measurement equipment, computer work stations (and associated software) and other instruments or systems used in the preparation or use of Nucleic Acid Arrays or the extraction or processing of data from Nucleic Acid Arrays.

Patent Rights means U.S Patents #5,700,637 and 5,436,327 and International Application No. PCT/GB/89/00460 and PCT/GB/89/01114 and all continuations, continuations-in-part, divisionals, re-examinations and reissues, and any patents issuing therefrom or claiming common priority thereto, together with any other patents which issue to Licensor, or which otherwise come into the ownership or under the control of Licensor during the Term and which Licensor has the right to license, and which relate, but only to the extent that they relate, to the general use of Nucleic Acid Arrays, including methods for making or analyzing Nucleic Acid Arrays and for creating Licensee Ratio-based Databases, but excluding therefrom any such patents that relate but only to the extent that they relate to instrumentation for the reading of Nucleic Acid Arrays, the design of probes for use on Nucleic Acid Arrays, particular sequences used on Nucleic Acid Arrays, software used in instrumentation for reading Nucleic Acid Arrays or in probe design, microfluidics or the control or assurance of the quality of Nucleic Acid Arrays.
5,700,637 – Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
5,436,327 – Support-bound oligonucleotides

Licensed Product means a Nucleic Acid Array and any component thereof, an Instrument, kit, reagent, computer software or other product, apparatus or composition of matter of whatever nature which is Covered by a Valid Claim, but not including a Database or other information (other than a Database or information which is an integral part of a product).

In-Situ Inkjet Synthesis means a method for the fabrication of Nucleic Acid Arrays on a solid support by synthesizing by chemical means individual nucleic acids directly on such solid support at specific locations on the Nucleic Acid Array using an inkjet printing device to deliver to defined locations on the surface of the solid support precursors for or reagents which allow mononucleotide additions.

Incyte Expression Database means a Database consisting entirely or substantially of gene expression data and containing at least five hundred data points, where a single data point is data relating to the level of expression of one gene in one sample.

Database means a collection of information derived from one or more Nucleic Acid Arrays, which is licensed for value to multiple third parties, but does not include a database for internal use exclusively by an Entity.

Field of Use
This agreement pertain to the drug industry in all fields other than the Excluded Fields.

Excluded Fields means any of the following activities
            (a)   the use of a Nucleic Acid Array for or in connection with any activity other than gene expression profiling or non-commercial genotyping;
            (b)   the exercise of any of the rights licensed under this Agreement for the purposes of the manufacture, having manufactured, use, Supply, creation or contribution to the creation of Incyte Expression Databases; and
            (c)  [the manufacture or having manufactured of Nucleic Acid Arrays by a method other than In-Situ Inkjet Synthesis.

Licensee is  a leader in the emerging field of informational genomics. Informational genomics involves acquiring, storing, and analyzing gene expression information gathered from throughout a cell to identify a majority of the medically important drug targets and gene functions. Licensee combines the power of informatics and genomics to create a proprietary platform that accelerates and enhances the drug discovery process for pharmaceutical and biotechnology companies and improves agricultural products.

IPSCIO Record ID: 383582

License Grant
In the original agreement, Licensor granted
— For the Layton and Stanford Patent Rights a nonexclusive, non-transferrable, limited sub-licensable, world-wide license under the Layton Patent Rights and the Stanford Patent Rights to practice and use the subject matter within the Layton Patent Rights and the Stanford Patent Rights in the Licensee Database Field of Use, Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use.
— For the Montefiore Patent Rights, a non-transferrable, limited sub-licensable, world-wide license under the Montefiore Patent Rights to practice and use the subject matter within the Montefiore Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use.
— For the Cancer Marker Patent Rights, Licensor grants a non-transferrable, limited sub-licensable, world-wide license under the Cancer Marker Patent Rights to practice and use the subject matter within the Cancer Marker Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use, only with respect to cancer.
— For the Database Patent Rights and Seilhamer/Scott Patent Rights, Licensor grants a nonexclusive, non-transferable, non-sublicensable , world-wide license under the Database Patent Rights and Seilhamer/Scott Patent Rights to practice and use the subject matter within the Database Patent Rights and the Seilhamer/Scott Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use, and the Personalized Research Field of Use.
— For the Sublicenses, Licensee shall have the right to grant sublicenses to third parties under such Patent Rights on a Product-by-Product basis to make, use, import, sell, and offer for sale Products developed by Licensee or its Affiliates.
— For the Co-Exclusive Licenses in the Homebrew and Diagnostic Fields of Use, Co-Exclusive shall mean that each Party has the right to exercise all of the rights under the Patent Rights in question in the field of use for which the parties have co-exclusive rights, without obligation to the other except to the extent provided in this Agreement, and neither Party alone has the right to grant sublicenses to third parties under such Patent Rights without express written consent of the other Party.
License Property
Cancer Marker Patent Rights shall mean all Valid Claims listed in any of the following patents and patent applications, to the extent that they are owned by Licensor with the right to license under this Agreement, and to the extent that they claim the composition of matter or use of any nucleic acids or proteins as markers or diagnostics for cancer.

The patents include
— Processes for Genetic Manipulations Using Promoters;
— Method for Detecting Pathological Conditions;
— Comparative Gene Transcript Analysis; and,
— Methods for Fabricating Micro Arrays of Biological Samples.

Field of Use
Licensee licenses various classes of patents from Licensor pertaining to the manipulation of genes, the detection of pathological conditions, comparative gene analysis, methods for fabricating tests of biological samples and the use of proteins as markers for cancers.

IPSCIO Record ID: 291167

License Grant
Licensee and Licensor will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensee-Licensor Exclusive Targets and the Licensor Exclusive Targets. For each Licensee-Licensor Exclusive Target, Licensor will provide Splicing Modulators to be tested for their ability to modulate splicing.

Licensee and Licensor will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensee-Licensor Exclusive Targets and the Licensor Exclusive Targets. For each Licensee-Licensor Exclusive Target, Licensor will provide Splicing Modulators to be tested for their ability to modulate splicing.

General Overview. Licensee and Licensor will identify and develop Splicing Modulators that modulate the splicing of Licensee-Licensor Exclusive Targets and Licensor Exclusive Targets, as more specifically described in the Research Plan.

Licensor grants Licensee the following licenses
Licensor grants Licensee an exclusive worldwide license to the Licensor Patents solely to research, develop, offer for sale, sell, import and export Licensee-Licensor Exclusive Products.

License Property
Product means an Licensee-Licensor Exclusive Product or an Licensor Exclusive Product, or both.

Licensor-Licensee Exclusive Products are a fixed pool of exclusive Gene Targets for research and development efforts to discover and develop Products that modify such exclusive Gene Targets to develop Splicing Modulators.

Licensor owns or controls certain patents related to morpholino chemistry.

Licensee-Licensor Exclusive Product means a Splicing Modulator that modulates an Licensee-Licensor Exclusive Target and that is Covered by the Licensor Patents and/or an Licensee Invention Patent.

Licensor Exclusive Product means a Splicing Modulator that modulates an Licensor Exclusive Target and is Covered by the Splicing Patents and/or an Licensor Invention Patent.

Splicing Modulator means an oligonucleotide or analog thereof that selectively modulates RNA Splicing or polyadenylation by a non-Rnase dependent mechanism at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective pattern of gene expression.

Licensor Patents means the patent(s) listed.
5,142,047 – Uncharged polynucleotide-binding polymers

Splicing Patents means the Isis Splicing Patents and the Licensee Splicing Patents.

Licensee Splicing Patents means the patent(s) listed.
5,976,879 – Antisense oligonucleotides which combat aberrant splicing and methods of using the same

Isis Splicing Patents means the patent(s) listed.
6,210,892 – Alteration of cellular behavior by antisense modulation of mRNA processing

Licensor Invention Patent and/or Licensee Invention Patent has the meaning depending how any Inventions are made under the Research Plan will define if it is an Licensee Invention or an Licensor Invention, as the case may be, and Patents claiming such Inventions will be Licensee Invention Patents or Licensor Invention Patents, respectively.

Licensee-Licensor Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
TNFRl
TNFR2
He.r2
BCL-X
CD28

Licensor Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
PDl
CTLA4
TGF beta
P53
IL23

Field of Use
This agreement pertains to the drug industry related to RNA splicing in the areas of drug discovery and medicinal chemistry,
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.